To Improve Our Patent System, We Must End Fee DiversionTo Improve Our Patent System, We Must End Fee Diversion
March 1, 2004
Originally Published MX March/April 2004
INDUSTRY ASSOCIATIONS
Legislation to restructure funding for the patent office will help ensure adequate review and protection of medtech intellectual properties.
Benjamin H. Wallfisch
The U.S. Patent and Trademark Office (PTO) serves a critical role for medtech companies. A healthy and predictable patent review system is essential for the medical device industry. Innovators need to be able to protect their inventions, and patent and trademark reviews must be thorough and timely.
Benjamin H. Wallfisch is policy director of the Medical Device Manufacturers Association (MDMA; Washington, DC). MDMA has joined with other organizations in the 21st Century Intellectual Property Coalition to encourage Congress to address the issue of patent fee diversion. |
About the Author
You May Also Like